Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules
more efficiently to pathological sites and by attenuating their accumulation in healthy organs …

Cancer is still ranked among the top three causes of death in the 30-to 69-year-old age
group in most countries and carries considerable societal and macroeconomic costs that …

Delivering drugs selectively to tumor tissues is a significant challenge in cancer therapy, and
pH-responsive polymeric assemblies have shown great potential in achieving this goal. In …

Docetaxel (DTX) has become one of the most important cytotoxic drugs to treat cancer;
nevertheless, its poor hydrophilicity and non-specific distribution of DTX lead to detrimental …

Objective Recurrent platinum-resistant ovarian cancer has a poor prognosis with limited
therapeutic options. Sub‐therapeutic intra-tumoral drug concentrations may add to therapy …

Controlled manufacturing and long-term stability are key challenges in the development and
translation of nanomedicines. This is exemplified by the mRNA-nanoparticle vaccines …

Background Paclitaxel (PTX) is widely used in the treatment of advanced esophageal and
gastric cancer. Polymeric micelles can improve the drug-loading efficiency of PTX. However …

Docetaxel (DTX) has been reported to be one of the most effective anticancer agents with
wide application in various cancer therapy. Conversely, it has under utilized clinical …

Nanocarriers have shown their ability to extend the circulation time of drugs, enhance tumor
uptake, and tune drug release. Therapeutic peptides are a class of drug compounds in …

Core-crosslinked polymeric micelles (CCPMs) are an attractive class of nanocarriers for
drug delivery. Two crosslinking approaches to form CCPMs exist: either via a low-molecular …